Pharsight

1. List of Rayaldee drug patents

Application	Filing Date	Opposition Party	Legal Status
EP16164563A	2022-08-23	DSM Nutritional Products Ltd	Granted and Under Opposition
EP19217651A	2022-02-07	DSM Nutritional Products AG	Granted and Under Opposition
EP18155036A	2021-05-26	DSM Nutritional Products AG	Granted and Under Opposition
EP14717038A	2021-04-21	DSM Nutritional Products AG	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9943530	EIRGEN	Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3	Feb, 2027 (3 years from now)
US8906410	EIRGEN	Oral dosage form of 25-hydroxyvitamin D	Feb, 2027 (3 years from now)
US10213442	EIRGEN	Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3	Feb, 2027 (3 years from now)
US8207149	EIRGEN	Method for treating secondary hyperparathyroidism in CKD	Apr, 2028 (4 years from now)
US8778373	EIRGEN	Methods for controlled release oral dosage of a vitamin D compound	Apr, 2028 (4 years from now)
US9408858	EIRGEN	Method for treating secondary hyperparathyroidism in CKD	Apr, 2028 (4 years from now)
US9925147	EIRGEN	Method for treating secondary hyperparathyroidism in CKD	Apr, 2028 (4 years from now)
US11154509	EIRGEN	Methods for controlled release oral dosage of a vitamin D compound	Apr, 2028 (4 years from now)
US9498486	EIRGEN	Method for controlled release oral dosage of a vitamin D compound	Apr, 2028 (4 years from now)
US8361488	EIRGEN	Methods and compositions for controlled release oral dosage of a vitamin D compound	Jul, 2028 (5 years from now)
US8426391	EIRGEN	Treating vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3	Aug, 2028 (5 years from now)
US9861644	EIRGEN	Stabilized modified release vitamin D formulation and method of administering same	Mar, 2034 (10 years from now)
US11253528	EIRGEN	Stabilized modified release Vitamin D formulation and method of administering same	Mar, 2034 (10 years from now)
US10300078	EIRGEN	Stabilized modified release vitamin D formulation and method of administering same	Mar, 2034 (10 years from now)
US10357502	EIRGEN	Stabilized modified release vitamin D formulation and method of administering same	Mar, 2034 (10 years from now)

Do you want to check out RAYALDEE patents from before 2022?

Drugs and Companies using CALCIFEDIOL ingredient

Market Authorisation Date: 17 June, 2016

Treatment: Maintaining serum 25-hydroxyvitamin d at a level of at least 30 ng/ml with oral, sustained release 25-hydroxyvitamin d; Treatment of secondary hyperparathyroidism in patients with stage 3 or 4 chronic...

Dosage: CAPSULE, EXTENDED RELEASE;ORAL